[eng] The endocannabinoid system and the cannabinoid CB1 receptors are involved in the development of ethanol tolerance and dependence. This study aimed to investigate the in vivo sensitivity of a CB1 receptor agonist (WIN 55,212-2) modulating the synthesis of 3,4-dihydroxyphenylalanine/dopamine/noradrenaline (DOPA/DA/NA) and that of 5-hydroxy-tryptophan/serotonin (5-HTP/5-HT) in rat brain after ethanol treatment and withdrawal. In control rats, WIN 55,212-2 (4 mg/kg, i.p., for 1 h), through a mechanism sensible to the CB1 antagonist SR 141716A, increased the synthesis of DOPA/NA in a slice of brainstem containing the locus ceruleus (250%) and in the hippocampus (64%), and it reduced DOPA/DA synthesis in the striatum (47%). WIN 55,212-2 als...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
BACKGROUND: Chronic ethanol administration results in neurobiological alterations similar to those o...
11 p., 5 figures and references.BACKGROUND: This study was undertaken to identify the neurochemical ...
This study investigated the effect of the new CB1 cannabinoid receptor antagonist, SR147778, on etha...
Abstract — Aims: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the etha...
International audienceAs the contribution of cannabinoid (CB1) receptors in the neuroadaptations fol...
Abstract — Aims: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the etha...
AIMS: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the ethanol prefere...
International audienceAs the contribution of cannabinoid (CB1) receptors in the neuroadaptations fol...
[eng] The in vivo sensitivity of presynaptic 5-HT1A receptors (autoreceptors and heteroreceptors) mo...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
1. Chronic alcohol exposure modifies endocannabinoid levels in different brain regions, while pharma...
Rationale: It has been suggested that endocannabinoid mechanisms are involved in the control of etha...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
BACKGROUND: Chronic ethanol administration results in neurobiological alterations similar to those o...
11 p., 5 figures and references.BACKGROUND: This study was undertaken to identify the neurochemical ...
This study investigated the effect of the new CB1 cannabinoid receptor antagonist, SR147778, on etha...
Abstract — Aims: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the etha...
International audienceAs the contribution of cannabinoid (CB1) receptors in the neuroadaptations fol...
Abstract — Aims: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the etha...
AIMS: The cannabinoid CB1 receptor antagonist, SR141716A, differentially affects the ethanol prefere...
International audienceAs the contribution of cannabinoid (CB1) receptors in the neuroadaptations fol...
[eng] The in vivo sensitivity of presynaptic 5-HT1A receptors (autoreceptors and heteroreceptors) mo...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
1. Chronic alcohol exposure modifies endocannabinoid levels in different brain regions, while pharma...
Rationale: It has been suggested that endocannabinoid mechanisms are involved in the control of etha...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...